Tackling supply chain challenges for a country at war
We are there for our patients – even in crisis regions. A supply chain success story with our Ukrainian colleague Tetiana Nagirna from Kyiv.
Search
Sales consultant about working with purpose
Bok talks about how he found purpose in his career. After his father was diagnosed with cancer, he decided to work as an oncology sales consultant.
Pradaxa US Litigation settlement
100-year anniversary of BI in respiratory care
100-year anniversary of Boehringer Ingelheim in respiratory care
Partnership canine oncology
The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Boehringer Ingelheim reaches more patients than ever, innovation drives growth
Boehringer Ingelheim reports a strong performance in 2022.
Veterinary oncology experts meet in Germany
Veterinary oncology experts meet prior to the European Society of Veterinary Oncology Congress in Hofheim, Germany
Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
VSV-GP
VSV-GP
Five facts everyone should know about heartworms
Heartworms are dangerous parasites that can infest pets through mosquito bites, causing serious illness. Here are five key facts we all should know about heartworms.
Boehringer Ingelheim acquires Nerio Therapeutics
Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics
Who are we?
Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Our Asthma Products
Our Asthma Products
Collaboration Boehringer Ingelheim Veeva technology
Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
ArisGlobal acquires Boehringer Ingelheim technology
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Human-dog relationship – a historical perspective
The human-dog relationship – a historical perspective
Rabies prevention local action partnering organizations
Global rabies prevention needs local action. Together with partnering organizations, we’re using pilot projects to find the right approach.
Boehringer Ingelheim Innovation Prize
Find out more about how we’re providing valuable resources to life-science innovators to enable new and emerging science
digital_leader_award_2020
Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award
clinical-collaboration-with-Amgen
Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
inauguration_biopharmaceutical_production_facility_vienna
The state-of-the-art biopharmaceutical production facility in Vienna is the single largest investment in the company's history.
Veronika Kohlbrenner
Veronika Kohlbrenner, Patient Safety Physician in Therapeutic Area Inflammation, tells us how she is able to work across different levels of the drug development process.
Breakthrough in Artificial Intelligence ChatGPT
Is ChatGPT the AI revolution we were waiting for or only media hype? Experts from Boehringer Ingelheim take a close look.
Boehringer Ingelheim announces collaboration with MabGenesis
Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
DiaTEC new purification technology Ingelvac CircoFLEX
Boehringer Ingelheim introduces DiaTEC, a new and proprietary purification technology for Ingelvac CircoFLEX®